{"prompt": "['Appendix 7', 'NYHA Functional Classification System for Heart Failure and LVSD', 'NCI CTCAE V4.0 Grading', 'LVSD NCI CTCAE V4 Grading', 'Investigations', 'Grade', '1', '2', '3', '4', '5', 'EF decreased', '-', 'Resting EF', 'Resting EF', 'Resting EF', '-', '[a]', '50% 40%;', '39% 20%;', '< 2050%', '10% 19%', '> 20% drop', 'drop from', 'from baseline', 'baseline', 'ittps://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf page 109)', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '9 / Protocol MO40628, Version 2']['TABLE OF CONTENTS', '1.', 'BACKGROUND', '29', '1.1', 'Background on HER2-Positive Early Breast Cancer', '29', '1.2', 'Background on Study Medications', '30', '1.2.1', 'Study Drug Nomenclature', '30', '1.2.2', 'Background on Perjeta', '30', '1.2.3', 'Background on Herceptin', '31', '1.2.4', 'Background on Pertuzumab and Trastuzumab Fixed-Dose', 'Combination for Subcutaneous Administration', '31', '1.3', 'Study Rationale and Benefit-Risk Assessment', '33', '1.3.1', 'Study Rationale', '33', '1.3.2', 'Benefit-Risk Assessment', '34', '2.', 'OBJECTIVES AND ENDPOINTS', '34', '2.1', 'Objectives', '35', '2.1.1', 'Primary Objective', '35', '2.1.2', 'Secondary Objectives', '35', '2.1.2.1', 'Secondary Safety Objectives', '35', '2.1.2.2', 'Secondary Efficacy Objective', '36', '3.', 'STUDY DESIGN', '36', '3.1', 'Description of the Study', '36', '3.2', 'End of Study and Length of Study', '39', '3.3', 'Rationale for Study Design', '40', '3.3.1', 'Rationale for Perjeta IV, Herceptin IV, and Pertuzumab and', 'Trastuzumab FDC SC Doses and Schedules', '40', '3.3.2', 'Rationale for Patient Population', '40', '3.3.3', 'Rationale for Randomization Stratification Factors', '40', '3.3.4', 'Rationale for Randomized Cross-Over Design', '41', '3.3.5', 'Rationale for Patient Reported Outcome Assessments', '41', '4.', 'MATERIALS AND METHODS', '42', '4.1', 'Patients', '42', '4.1.1', 'Inclusion Criteria', '42', '4.1.2', 'Exclusion Criteria', '44', '4.2', 'Method of Treatment Assignment', '45', '4.3', 'Study Treatment', '46', '4.3.1', 'Study Treatment Formulation, Packaging, and Handling', '46', '4.3.1.1', 'Pertuzumab and Trastuzumab FDC SC', '46', '4.3.1.2', 'Perjeta IV', '46', '4.3.1.3', 'Herceptin IV', '46', '4.3.2', 'Study Treatment Dosage, Administration, and Compliance', '46', '4.3.2.1', 'Pertuzumab and Trastuzumab FDC SC', '47', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '10 / Protocol MO40628, Version 2']['4.3.2.2', 'Perjeta IV', '47', '4.3.2.3', 'Herceptin IV', '47', '4.3.3', 'Investigational Medicinal Product Accountability', '48', '4.3.4', 'Continued Access to Pertuzumab and Trastuzumab FDC SC,', 'Perjeta IV and Herceptin IV', '48', '4.4', 'Concomitant Therapy', '48', '4.4.1', 'Permitted Therapy', '49', '4.4.2', 'Cautionary Therapy', '49', '4.4.3', 'Prohibited Therapy', '50', '4.5', 'Study Assessments', '50', '4.5.1', 'Informed Consent Forms and Screening Log', '50', '4.5.2', 'Medical History, Concomitant Medication, and Demographic', 'Data', '51', '4.5.3', 'Pathology', '51', '4.5.4', 'Physical Examinations', '51', '4.5.5', 'Vital Signs', '51', '4.5.6', 'ECOG Performance Status', '51', '4.5.7', 'Clinical Breast Examination', '52', '4.5.8', 'Mammograms', '52', '4.5.9', 'Diagnosis of Breast Cancer Recurrence or Second Primary', 'Cancer', '52', '4.5.10', 'Cardiac Function', '53', '4.5.11', 'Laboratory Samples', '53', '4.5.12', 'Patient Reported Outcomes', '53', '4.5.12.1', 'Patient Preference Questionnaire', '54', '4.5.12.2', 'Therapy Administration Satisfaction Questionnaires', '54', '4.5.12.3', 'European Organisation for Research and Treatment of', 'Cancer Quality of Life Questionnaire (EORTC QLQ-C30)', '54', '4.5.13', 'Healthcare Professional Reported Outcomes', '54', '4.5.13.1', 'Healthcare Professional Questionnaire', '54', '4.6', 'Treatment, Patient, Study, and Site Discontinuation', '54', '4.6.1', 'Study Treatment Discontinuation', '54', '4.6.2', 'Patient Discontinuation from Study', '55', '4.6.3', 'Study Discontinuation', '55', '4.6.4', 'Site Discontinuation', '55', '5.', 'ASSESSMENT OF SAFETY', '56', '5.1', 'Safety Plan', '56', '5.1.1', 'Risks Associated with Pertuzumab', '56', '5.1.1.1', 'Hypersensitivity Reactions / Anaphylaxis and Administration-', 'Related Reactions', '56', '5.1.1.2', 'Symptomatic Left Ventricular Systolic Dysfunction', '57', '5.1.1.3', 'Epidermal Growth Factor Receptor (HER1)-Related', 'Toxicities', '58', '5.1.2', 'Risks Associated with Trastuzumab', '59', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '11 / Protocol MO40628, Version 2']\n\n###\n\n", "completion": "END"}